Novozymes' US growth outlook dwindles

Surprisingly poor development in the US bioethanol market prompts Novozymes to downgrade its annual organic growth guidance to 3-5 percent against the prior spread of 3-6 percent.
Photo: Novozymes/ PR
Photo: Novozymes/ PR

Novozymes' bioenergy division had a surprisingly poor early 2019. With DKK 623 million (EUR 83.4 million) in divisional revenue, Q1 sales retreated by 8 percent relative to the same period last year, further contributing to an aggregated net result decline of almost DKK 100 million to DKK 697 million. This fall was the primary factor behind the downgraded organic growth guidance, adjusted from 3-6 to 3-5 percent, shows the company's first quarter interim report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading